The PennZone

  • Home
  • Non-profit
  • Music
  • Marketing
  • Books
  • Entertainment
  • Health
  • Automotive
  • Business

HotSpot Therapeutics to Present Additional Preclinical Data on Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma
The PennZone/10270943

Trending...
  • LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
  • Jacombs Tickets Partners with UEFA to Offer Champions League Tickets
  • Timbrana Helps General Contractors Improve Jobsite Visibility and Subcontractor Accountability
BOSTON, May 20, 2024 ~ Journalist: HotSpot Therapeutics, Inc. has announced that they will be presenting additional preclinical data from their MALT1 program at the 4th American Association for Cancer Research (AACR) International Meeting. The meeting, titled "Advances in Malignant Lymphoma," will take place from June 19-22, 2024 in Philadelphia, PA.

The company, known for pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," will be sharing their findings on the highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program.

More on The PennZone
  • Corner Property Management AAMC Expands Presence with Clover Mill Management Agreement
  • Michael Fischer Launches 'Legacy League' Podcast
  • Keystone Consulting Engineers Marks Next Chapter of Growth with Refreshed Brand
  • AutoProIT Achieves Cyber Essentials Certification, Reinforcing Its Commitment to Secure Digital Transformation
  • DayPass llega a ChatGPT y Claude

The presentation, titled "Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas," will take place on Thursday, June 20, 2024 from 5:30-7:30 PM ET at the Sheraton Philadelphia Downtown. The publication number for this presentation is PO-036.

HotSpot Therapeutics' innovative approach to targeting regulatory sites on proteins has shown promising results in their MALT1 program and could potentially lead to new treatments for non-Hodgkin lymphomas. The company's participation in the AACR International Meeting highlights their commitment to advancing cancer research and finding new ways to treat this disease.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
  • Revinate launches hospitality's first data activation platform
  • HLN Consulting Names Lilly Kan as Its First Chief Executive Officer
  • BitTitan Accelerates Large-Scale Document Migrations with MigrationWiz
  • Clearnetworx Deploys netElastic vBNG, CGNAT And netVision To Power Fiber Expansion Across Colorado's Western Slope
  • Glenn Strange - Iconic Horror actor of Universal Studios Frankenstein's Monster Fame Honored
  • Creole101 Launches Multilingual Dictionary App with 50,000+ Entries, Vocabulary Games and Haitian Cultural Resources
  • Hilton Waikiki Beach Resort & Spa Introduces Level 37 Sky Lounge by Casamigos
  • Self-Published Dad's Santa Book Finally Found After 3 Years on Amazon
  • Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX
  • Roots for Boots to Participate in 2026 Adams County Community Foundation Giving Spree
  • Timbrana Helps General Contractors Improve Jobsite Visibility and Subcontractor Accountability
  • Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1
  • Vegan Kingz Expands Direct-Import Wholesale Lineup to Help Commercial Kitchens Cut Ingredient Costs
  • Acuvance Survey Finds ERP Integration Remains a Key Challenge as Healthcare Organizations Prepare for AI
  • Everything Policy Unveils Their Classroom Resources Behind Every Policy Topic
  • Constantine "Costa" Kapothanasis II Acquires The Lubri-Loy Company, Carrying a 77-Year-Old American Lubricant Brand Into Its Next Era
  • LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
  • Danish company biosuite introduces biotech procurement software to track outsourced R&D commitments
  • Ten Ten Ten Announces Alento, Its Initiative to Help Independent Primary Care Thrive

Popular on PennZone

  • Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers - 115
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh
  • Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville
  • Can Government Operate Better Through Innovation?
  • New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
  • Her Song Lives On: Remembering Mrs. Darlene Davis Porter
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
  • Curtis Salgado shares a love letter to the city of Chicago and Otis Rush with new single
  • World-Renowned Body Language Expert Mark Bowden Headlines INSPIRE Northwest 2026 in Wenatchee, WA
  • Most Indiana Plane Crashes Happen Away from the State's Major Airports

Similar on PennZone

  • UK Financial Ltd Announces Two-for-One Upgrade of Maya 3 to Maya 3G Token Using Chainlink Cross-Chain Technology
  • Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • AutoProIT Achieves Cyber Essentials Certification, Reinforcing Its Commitment to Secure Digital Transformation
  • Talented Learning Unveils 2026 LMS Award Winners
  • Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX
  • Acuvance Survey Finds ERP Integration Remains a Key Challenge as Healthcare Organizations Prepare for AI
  • Constantine "Costa" Kapothanasis II Acquires The Lubri-Loy Company, Carrying a 77-Year-Old American Lubricant Brand Into Its Next Era
  • JFAB Consulting to Celebrate New Brand with Private VIP Event at Acrisure Stadium
  • Industrial & systems engineering educator and professional to lead global strategic partnerships for professional society
  • Convergence of AI, Wearable Technology, Remote Patient Monitoring and Real-World Healthcare: PomDoctor Ltd. (N A S D A Q: POM)
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us